---
title: "Aurinia Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 77.71 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285550878.md"
datetime: "2026-05-07T12:25:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285550878.md)
  - [en](https://longbridge.com/en/news/285550878.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285550878.md)
---

# Aurinia Pharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 77.71 M

Revenue: As of FY2026 Q1, the actual value is USD 77.71 M, beating the estimate of USD 76.98 M.

EPS: As of FY2026 Q1, the actual value is USD 0.25, beating the estimate of USD 0.195.

EBIT: As of FY2026 Q1, the actual value is USD 38.92 M.

Aurinia Pharmaceuticals Inc. (Aurinia 制药) reported its financial results for the quarter ended March 31, 2026. The actual financial and operational metrics were not directly presented within the text of the Form 8-K itself but were part of an attached press release .

#### Total Revenue

For the three months ended March 31, 2026, total revenue was $77.7 million, marking a 24% increase from $62.5 million in the same period of 2025 .

#### Net Product Sales

Net product sales of LUPKYNIS reached $73.6 million for the three months ended March 31, 2026, which is a 23% increase from $60.0 million in the comparable period of 2025 .

#### License, Collaboration and Royalty Revenue

License, collaboration and royalty revenue from Otsuka totaled $4.1 million for the three months ended March 31, 2026, representing a 64% rise from $2.5 million in the same period of 2025 .

#### Net Income

Net income for the three months ended March 31, 2026, was $34.4 million, up 48% from $23.3 million in the same period of 2025 .

#### Operational Metrics (in thousands)

-   **Cost of revenue**: $6,505 for the three months ended March 31, 2026, compared to $8,574 for the same period in 2025 .
-   **Selling, general and administrative**: $22,029 for the three months ended March 31, 2026, compared to $20,339 for the same period in 2025 .
-   **Research and development**: $7,470 for the three months ended March 31, 2026, compared to $5,743 for the same period in 2025 .
-   **Restructuring**: $0 for the three months ended March 31, 2026, compared to $1,533 for the same period in 2025 .
-   **Other expense, net**: $279 for the three months ended March 31, 2026, compared to $4,429 for the same period in 2025 .
-   **Total operating expenses**: $36,283 for the three months ended March 31, 2026, compared to $40,618 for the same period in 2025 .
-   **Income from operations**: $41,422 for the three months ended March 31, 2026, compared to $21,847 for the same period in 2025 .

#### Cash Flow from Operating Activities

Cash flows from operating activities were $32.6 million for the three months ended March 31, 2026, a significant increase of 2408% from $1.3 million in the same period of 2025 .

#### Cash Position

As of March 31, 2026, Aurinia 制药 held cash, cash equivalents, restricted cash, and investments totaling $378.8 million, a decrease from $398.0 million at December 31, 2025 .

#### Cash Flows from Financing Activities

Cash outflows from financing activities amounted to - $53.7 million for the three months ended March 31, 2026 . This included the repurchase of 2.5 million common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million .

#### 2026 Total Revenue and Net Product Sales Guidance

Aurinia Pharmaceuticals Inc. reiterates its guidance for 2026 total revenue to be between $315 million and $325 million, representing an 11% to 15% increase compared to 2025 . The company also projects 2026 net product sales to range from $305 million to $315 million, an anticipated increase of 12% to 16% over 2025 .

### Related Stocks

- [AUPH.US](https://longbridge.com/en/quote/AUPH.US.md)

## Related News & Research

- [Aurinia Pharmaceuticals Completes Acquisition of Kezar Life Sciences](https://longbridge.com/en/news/285957581.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Hafnia’s Q1 2026 Financial Results Presentation to Be Held on 27 May 2026 | HAFN Stock News](https://longbridge.com/en/news/287014236.md)